Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | PRKCA | P17252 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | DGKA | P23743 | 1/20 | 0.38 |
| ▸ | PAM | P19021 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3835787 | 0.98 | TSHR (0.50) | TSHRLMNAALDH1A1RECQLPRKCA | |
| SCHEMBL3838294 | 0.98 | TSHR (0.50) | TSHRLMNAALDH1A1RECQLPRKCA | |
| SCHEMBL3829281 | 0.98 | TSHR (0.50) | TSHRLMNAALDH1A1RECQLPRKCA | |
| SCHEMBL15635179 | 0.92 | TSHR (0.54) | TSHRLMNAALDH1A1RECQLPRKCA | |
| SCHEMBL3835100 | 0.92 | DGKA (0.43) | TSHRLMNAALDH1A1PRKCAKMT2A | |
| SCHEMBL3833050 | 0.90 | DGKA (0.47) | TSHRLMNAALDH1A1PRKCAKMT2A | |
| SCHEMBL6662546 | 0.86 | PAM (0.51) | TSHRALDH1A1KMT2AMEN1DGKA | |
| SCHEMBL3835097 | 0.85 | TSHR (0.45) | TSHRLMNAALDH1A1KMT2AMEN1 | |
| Bis(Pivaloyloxymethyl) Succinate SCHEMBL3123390 | 0.83 | PRKCA (0.41) | TSHRALDH1A1PRKCADGKA | |
| SCHEMBL7326020 | 0.83 | CYP1A2 (0.50) | TSHRLMNAALDH1A1RECQLPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629383-B2 | Double esters | DRUG DISCOVERY LABORATORY AS (NO) | 2009-12-08 | — | — | US | disclosed |
| EP-1448508-B1 | DOUBLE ESTERS | DRUG DISCOVERY LAB AS (NO) | 2009-09-23 | — | — | EP | disclosed |
| US-20050203181-A1 | Double esters | DRUG DISCOVERY LABORATORY AS (NO) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203181-A1 | Double esters | ACACA, CES1, ACACB | TSHR 1933/4885LMNA 1955/4885ALDH1A1 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.